Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens

BACKGROUND: Patients with metastatic urothelial carcinoma (mUC) who progress after platinum-based chemotherapy have had few treatment options and uniformly poor outcomes. Atezolizumab (antiprogrammed death-ligand 1) was approved in the USA for cisplatin-ineligible and platinum-treated mUC based on I...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Eur Urol
Главные авторы: Perez-Gracia, Jose Luis, Loriot, Yohann, Rosenberg, Jonathan E., Powles, Thomas, Necchi, Andrea, Hussain, Syed A., Morales-Barrera, Rafael, Retz, Margitta M., Niegisch, Günter, Durán, Ignacio, Théodore, Christine, Grande, Enrique, Shen, Xiaodong, Wang, Jingjing, Nelson, Betty, Derleth, Christina L., van der Heijden, Michiel S.
Формат: Artigo
Язык:Inglês
Опубликовано: 2017
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7448222/
https://ncbi.nlm.nih.gov/pubmed/29273410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2017.11.023
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы